Document is current
Any future updates will be listed below
-
Authors
Miller, Colin G. https://orcid.org/0000-0002-9286-9787
Grønbæk, Henning
Virgolini, Irene
Kjaer, Andreas
Terve, Pierre
Bahri, Shadfar
Iversen, Peter
Svirydenka, Hanna
Rohban, Thomas
McEwan, Sandy
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03220217 at ClinicalTrials.govDocuments that mention this clinical trial
A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial
https://doi.org/10.1186/s13550-021-00819-1
-
Funding
Funding for this research was provided by:
Ipsen Biopharmaceuticals
- License Information
-
More Information
Article History
Received: 2 June 2021
Accepted: 4 August 2021
First Online: 6 September 2021
Declarations
:
: The study was performed in four investigational sites in Austria, Denmark and the United States, and was conducted in accordance with the Declaration of Helsinki as well as the Good Clinical Practice guidelines. Ethics committee approval was obtained at each participating site, and all patients provided written informed consent.
: Not applicable.
: CGM has acted as a consultant for Ipsen, CytoSite Bio and Alacrita, and is a managing partner at the Bracken Group. HG serves on the advisory board of Ipsen. IV has acted as a consultant for Ipsen and Advanced Accelerator Applications. AK has served on the advisory board of Ipsen. PT is an employee at Keosys. TR is a managing partner at Partner 4 Health, and has acted as a consultant for Ipsen. SM is an employee at Ipsen Bioscience (Cambridge, MA, USA). No other potential conflict of interest relevant to this article was reported.
